HC Wainwright Brokers Lift Earnings Estimates for Senseonics

Senseonics Holdings, Inc. (NYSE:SENS - Free Report) - Stock analysts at HC Wainwright increased their FY2027 EPS estimates for Senseonics in a research note issued to investors on Monday, July 14th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.02) per share for the year, up from their prior estimate of ($0.03). HC Wainwright has a "Buy" rating and a $1.40 price target on the stock. The consensus estimate for Senseonics' current full-year earnings is ($0.14) per share. HC Wainwright also issued estimates for Senseonics' FY2029 earnings at $0.03 EPS.

SENS has been the topic of several other research reports. Mizuho assumed coverage on shares of Senseonics in a report on Thursday, April 10th. They issued an "outperform" rating and a $2.00 target price on the stock. Lake Street Capital raised shares of Senseonics to a "strong-buy" rating in a report on Thursday. Wall Street Zen raised shares of Senseonics to a "sell" rating in a report on Monday, May 12th. Finally, TD Cowen assumed coverage on shares of Senseonics in a report on Tuesday. They issued a "buy" rating and a $1.25 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $1.55.

Senseonics Stock Performance

Senseonics stock traded up $0.02 on Wednesday, hitting $0.58. The company's stock had a trading volume of 11,834,920 shares, compared to its average volume of 7,371,543. The firm has a market cap of $379.38 million, a P/E ratio of -4.46 and a beta of 0.92. The company has a quick ratio of 2.38, a current ratio of 2.47 and a debt-to-equity ratio of 59.17. The company has a fifty day moving average price of $0.52 and a 200-day moving average price of $0.68. Senseonics has a one year low of $0.25 and a one year high of $1.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its position in Senseonics by 9.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,339,698 shares of the company's stock valued at $1,748,000 after purchasing an additional 274,842 shares during the period. Raymond James Financial Inc. acquired a new position in Senseonics during the 4th quarter valued at about $26,000. HighTower Advisors LLC acquired a new position in Senseonics during the 4th quarter valued at about $32,000. Virtu Financial LLC acquired a new position in Senseonics during the 4th quarter valued at about $148,000. Finally, Geode Capital Management LLC lifted its position in Senseonics by 9.7% during the 4th quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company's stock valued at $3,354,000 after purchasing an additional 566,704 shares during the period. Institutional investors and hedge funds own 12.36% of the company's stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.